EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Chemotherapy‐induced neutropenia predicts short‐term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid

Tomonori Araki iD, Tsuyoshi Shirakawa iD, Mototsugu Shimokawa, Taiga Otsuka, Kohei Hayashi, Yuki Sonoda, Takuya Honda, Hisamitsu Miyaaki, Junichi Nakazawa, Hozumi Shimokawa, Yudai Shinohara, Futa Koga und 20 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70072 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Tomonori Araki und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neutropenia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy‐induced neutropenia has been identified as a potential prognostic marker for multiple cancers. However, only one retrospective study, NN‐2301, has investigated the relationship between neutropenia and treatment effects of nanoliposomal irinotecan/5‐fluorouracil/folinic acid (NFF) in pancreatic cancer. In this prospective study, we aimed to clarify whether NFF‐induced neutropenia could serve as a prognostic marker in pancreatic cancer. Data were analyzed from the prospective cohort of the NAPOLEON‐2 trial, an observational study involving patients with unresectable pancreatic cancer treated with NFF. Neutropenia severity was categorized into three cutoffs: Cutoff A (Grade [Gr] 0 vs. Gr 1–4), cutoff B (Gr 0–1 vs. Gr 2–4), and Cutoff C (Gr 0–2 vs. Gr 3–4), using the Common Terminology Criteria for Adverse Events version 5.0, owing to conformity with previous studies and simplicity. The primary endpoint was overall survival (OS); progression‐free survival (PFS) was the secondary endpoint. The neutropenic groups included Gr 1, 2, 3, and 4, with 79, 23, 34, and 7 patients, respectively. At each cutoff, OS and PFS were significantly better in the severe neutropenia groups. Higher neutropenia grades correlated with improved OS (log‐rank trend test: χ 2 = 8.62, p < .01). Multivariate Cox regression analysis revealed significant differences for all cutoffs: adjusted hazard ratios were 0.57 (95% confidence interval [CI] 0.40–0.83) (Cutoff A), 0.53 (95% CI 0.36–0.78) (Cutoff B), and 0.52 (95% CI 0.34–0.80) (Cutoff C). NFF‐induced neutropenia is a valuable prognostic marker in pancreatic cancer and may guide treatment selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeutropeniaHumansLeucovorinMaleFemaleIrinotecanFluorouracilMiddle AgedAgedLiposomesProspective StudiesPrognosisAdult

Stichwörter der Autor:innen

nanoliposomal irinotecanneutropeniaobservational studypancreatic cancerprognostic marker

Substanzen

LeucovorinIrinotecanFluorouracilLiposomes

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
  • Clinical Hematology Oncology Treatment Study Group, Fukuoka, Fukuoka, Japan.
  • Director of Medical Checkup Center, Eikoh Hospital, Kasuya, Fukuoka, Japan.
  • Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Fukuoka, Japan.
  • Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.
  • Department of Internal Medicine, Minato Medical Clinic, Fukuoka, Fukuoka, Japan.

ORCID-Profile: Tomonori Araki, Tsuyoshi Shirakawa

Zitieren

APA

Araki, T., Shirakawa, T., Shimokawa, M., Otsuka, T., Hayashi, K., Sonoda, Y., Honda, T., Miyaaki, H., Nakazawa, J., Shimokawa, H., Shinohara, Y., Koga, F., Oza, N., Oda, H., Takeshita, S., Arima, S., Arita, S., Kawaguchi, Y., Nishikawa, K., …, & Mitsugi, K. (2026). Chemotherapy‐induced neutropenia predicts short‐term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid. International Journal of Cancer. https://doi.org/10.1002/ijc.70072

Vancouver

Araki T, Shirakawa T, Shimokawa M, Otsuka T, Hayashi K, Sonoda Y, et al. Chemotherapy‐induced neutropenia predicts short‐term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid. International Journal of Cancer. 2026. doi:10.1002/ijc.70072

BibTeX
@article{Araki2026,
  author = {Araki, Tomonori and Shirakawa, Tsuyoshi and Shimokawa, Mototsugu and Otsuka, Taiga and Hayashi, Kohei and Sonoda, Yuki and Honda, Takuya and Miyaaki, Hisamitsu and Nakazawa, Junichi and Shimokawa, Hozumi and Shinohara, Yudai and Koga, Futa and Oza, Noriko and Oda, Hisanobu and Takeshita, Shigeyuki and Arima, Shiho and Arita, Shuji and Kawaguchi, Yasunori and Nishikawa, Kazuo and Otsu, Satoshi and Taguchi, Hiroki and Jikuya, Kenichi and Sakai, Tatsunori and Ueda, Yujiro and Sakae, Takahiro and Araki, Norimasa and Sawase, Hironori and Ide, Yasushi and Kawahira, Machiko and Nio, Kenta and Mizuta, Toshihiko and Mitsugi, Kenji},
  title = {Chemotherapy‐induced neutropenia predicts short‐term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70072}
}
Kostenlos starten →